Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st
June 14 2018 - 8:00AM
Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing
novel, first-in-class therapeutics to address the medical needs of
patients with kidney and vascular diseases, today announced that
Company management will present at the JMP Securities Life Sciences
Conference in New York City on Thursday, June 21, 2017 at 11:00 am
ET.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health
of patients with kidney and vascular diseases through the
development of novel, first-in-class therapeutics. Proteon's lead
product candidate, vonapanitase, is an investigational drug
intended to improve hemodialysis vascular access outcomes. Proteon
is evaluating vonapanitase in patients with chronic kidney disease
(CKD) undergoing surgical creation of a radiocephalic arteriovenous
fistula. Proteon is also evaluating vonapanitase in a Phase 1
clinical trial in patients with peripheral artery disease (PAD).
For more information, please visit www.proteontx.com.
Investor ContactGeorge Eldridge, Proteon
Therapeutics, Senior Vice President and Chief Financial
Officer781-890-0102geldridge@proteontherapeutics.com
Media ContactAnn Stanesa, Ten
Bridge
Communications617-230-0347proteon@tenbridgecommunications.com
Proteon Therapeutics (NASDAQ:PRTO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Proteon Therapeutics (NASDAQ:PRTO)
Historical Stock Chart
From Apr 2023 to Apr 2024